Published in
American Society for Microbiology, Microbiology Spectrum, 1(11), 2023
DOI: 10.1128/spectrum.04103-22
Links
Tools
Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
,
Thomas Theo Brehm ,
Marlene Fischer,
Andreas Heyer,
Dominic Wichmann,
Sabine Jordan,
Dominik Nörz ,
Marc Lütgehetmann,
Marylyn M. Addo,
Ansgar W. Lohse,
Stefan Schmiedel,
Stefan Kluge,
Julian Schulze zur Wiesch
Full text: Download
Abstract
This study shows that among hospitalized patients with SARS-CoV-2 Omicron variant infection at risk of disease progression, treatment with sotrovimab alone or in combination with remdesivir did not decrease in-hospital mortality. These real-world clinical findings in combination with previous in vitro data about lacking neutralizing activity of sotrovimab against SARS-CoV-2 Omicron variant do not support sotrovimab as a treatment option in these patients.